According to the design of the trials, a first phase will include minors of school age between 12 and 18, and it will involve those aged 5 to 11 later, Dr. Rolando Perez, director of Science and Innovation in the Entrepreneurial Group of the Biotechnology and Pharmaceutical Industries of Cuba (BioCubafarma), announced
The expert explained that the vaccine candidates to be used will be Soberana 01 and Soberana 02, which were developed by the Finlay Vaccines Institute (IFV) and has proven to be very safe so far.
During a press conference on the epidemiological situation in Cuba and the world, Dr. Perez informed that the request to carry out the trials will be submitted in April to the Center for State Control of Medicines, Equipment and Medical Devices (CECMED), the top regulating authority in in the country.
jg/mgt/rbp